Multiple sclerosis in 2020
Recent developments in the management of multiple sclerosis (MS) are ushering in a new era in MS treatment. The novel therapeutic disease-modifying agents that have been recently approved for the treatment of MS are B-cell therapies and various sphingosine-1-phosphate inhibitors. The Bruton's t...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publications
2021-01-01
|
| Series: | Apollo Medicine |
| Subjects: | |
| Online Access: | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2021;volume=18;issue=3;spage=196;epage=199;aulast=Rohatgi |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846146937727746048 |
|---|---|
| author | Anshu Rohatgi Neha Pandita |
| author_facet | Anshu Rohatgi Neha Pandita |
| author_sort | Anshu Rohatgi |
| collection | DOAJ |
| description | Recent developments in the management of multiple sclerosis (MS) are ushering in a new era in MS treatment. The novel therapeutic disease-modifying agents that have been recently approved for the treatment of MS are B-cell therapies and various sphingosine-1-phosphate inhibitors. The Bruton's tyrosine kinase inhibitor therapies provide a novel therapeutic approach in the treatment of MS. Numerous studies have demonstrated a high degree of efficacy with autologous hematopoietic stem cells. There are upcoming trials focusing on remyelination strategies in MS. In this yearly review, we will focus on all these latest developments which are leading to a promising change in the diagnosis, treatment, and prognosis of this disease. |
| format | Article |
| id | doaj-art-0ddc164819dd420baf3d54e1b09690cd |
| institution | Kabale University |
| issn | 0976-0016 2213-3682 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | SAGE Publications |
| record_format | Article |
| series | Apollo Medicine |
| spelling | doaj-art-0ddc164819dd420baf3d54e1b09690cd2024-12-02T00:26:43ZengSAGE PublicationsApollo Medicine0976-00162213-36822021-01-0118319619910.4103/am.am_90_21Multiple sclerosis in 2020Anshu RohatgiNeha PanditaRecent developments in the management of multiple sclerosis (MS) are ushering in a new era in MS treatment. The novel therapeutic disease-modifying agents that have been recently approved for the treatment of MS are B-cell therapies and various sphingosine-1-phosphate inhibitors. The Bruton's tyrosine kinase inhibitor therapies provide a novel therapeutic approach in the treatment of MS. Numerous studies have demonstrated a high degree of efficacy with autologous hematopoietic stem cells. There are upcoming trials focusing on remyelination strategies in MS. In this yearly review, we will focus on all these latest developments which are leading to a promising change in the diagnosis, treatment, and prognosis of this disease.http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2021;volume=18;issue=3;spage=196;epage=199;aulast=Rohatgiautologous hematopoietic stem cell transplantb-cell therapiesmultiple sclerosisneuroprotection |
| spellingShingle | Anshu Rohatgi Neha Pandita Multiple sclerosis in 2020 Apollo Medicine autologous hematopoietic stem cell transplant b-cell therapies multiple sclerosis neuroprotection |
| title | Multiple sclerosis in 2020 |
| title_full | Multiple sclerosis in 2020 |
| title_fullStr | Multiple sclerosis in 2020 |
| title_full_unstemmed | Multiple sclerosis in 2020 |
| title_short | Multiple sclerosis in 2020 |
| title_sort | multiple sclerosis in 2020 |
| topic | autologous hematopoietic stem cell transplant b-cell therapies multiple sclerosis neuroprotection |
| url | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2021;volume=18;issue=3;spage=196;epage=199;aulast=Rohatgi |
| work_keys_str_mv | AT anshurohatgi multiplesclerosisin2020 AT nehapandita multiplesclerosisin2020 |